Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

PepGen Inc. (PEPG)

15.23   -1.65 (-9.77%) 03-24 16:00
Open: 20 Pre. Close: 16.88
High: 20 Low: 14.27
Volume: 41,759 Market Cap: 360(M)

Technical analysis

as of: 2023-03-24 4:28:45 PM
Stoxline posted a SELL today, downgraded from higher rating. Downward movement to be expected.
Target: Six months: 20.01     One year: 23.36
Support: Support1: 12.51    Support2: 10.4
Resistance: Resistance1: 17.13    Resistance2: 20
Pivot: 15.81
Moving Average: MA(5): 16.51     MA(20): 15.73
MA(100): 15.09     MA(250): 0
MACD: MACD(12,26): 0     Signal(9): -0.1
Stochastic oscillator: %K(14,3): 57.7     %D(3): 70.9
RSI: RSI(14): 46
52-week: High: 20  Low: 4.32
Average Vol(K): 3-Month: 47 (K)  10-Days: 41 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.
[ PEPG ] has closed above bottom band by 39.0%. Bollinger Bands are 49.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 20.05 - 20.15 20.15 - 20.23
Low: 14.07 - 14.17 14.17 - 14.25
Close: 15.08 - 15.24 15.24 - 15.37

Company Description

PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.

Headline News

Sat, 25 Mar 2023
PepGen Inc (PEPG) Q4 2022 Earnings Call Transcript - Finnoexpert

Sat, 25 Mar 2023
PepGen (NASDAQ:PEPG) Given New $22.00 Price Target at ... - MarketBeat

Fri, 24 Mar 2023
Why Scholastic Shares Are Trading Lower By 23%? Here Are Other ... - UK

Thu, 23 Mar 2023
PepGen Reports Fourth Quarter and Full Year 2022 Financial ... - GlobeNewswire

Thu, 23 Mar 2023
PepGen Inc (PEPG) is higher by 12.59% in a Week, Should You Sell? - InvestorsObserver

Sat, 18 Mar 2023
PepGen (PEPG) Set to Announce Quarterly Earnings on Thursday - MarketBeat

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Underperform
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Underperform
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Biotechnology
Shares Out. 24 (M)
Shares Float 9 (M)
% Held by Insiders 32 (%)
% Held by Institutions 79.2 (%)
Shares Short 209 (K)
Shares Short P.Month 264 (K)

Stock Financials

EPS -3.06
EPS Est Next Qtl 0
EPS Est This Year 0
EPS Est Next Year 0
Book Value (p.s.) 8.18
Profit Margin (%) 0
Operating Margin (%) 0
Return on Assets (ttm) -20.4
Return on Equity (ttm) -36.9
Qtrly Rev. Growth 0
Gross Profit (p.s.) 0
Sales Per Share 0
EBITDA (p.s.) -2.46
Qtrly Earnings Growth 0
Operating Cash Flow -52 (M)
Levered Free Cash Flow -31 (M)

Stock Valuations

PE Ratio -4.98
PEG Ratio 0
Price to Book value 1.85
Price to Sales 0
Price to Cash Flow -6.94

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.